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New data sources for the analysis of cancer data are rapidly supplementing the large number of gene-expression markers used
for current methods of analysis. Significant among these new sources are copy number variation (CNV) datasets, which typically
enumerate several hundred thousand CNVs distributed throughout the genome. Several useful algorithms allow systems-level
analyses of such datasets. However, these rich data sources have not yet been analyzed as deeply as gene-expression data. To address
this issue, the extensive toolsets used for analyzing expression data in cancerous and noncancerous tissue (e.g., gene set enrichment
analysis and phenotype prediction) could be redirected to extract a great deal of predictive information fromCNVdata, in particular
those derived from cancers. Here we present a software package capable of preprocessing standard Agilent copy number datasets
into a form to which essentially all expression analysis tools can be applied. We illustrate the use of this toolset in predicting the
survival time of patients with ovarian cancer or glioblastoma multiforme and also provide an analysis of gene- and pathway-level
deletions in these two types of cancer.
1. Introduction
Copy number variations (CNVs) are promising DNA-level
biomarkers of cancer subtype. CNVs can influence the
phenotypes of cancer by disrupting (i.e., removing) or dupli-
cating (i.e., adding) copies of a gene [1]. Although CNV
studies have developed considerably over time [2–5], little is
known about how CNVs affect cancer pathogenesis.
Previous studies describe several software packages useful
for analysis of CNVs [6–8], primarily focused on identifying
significant copy number alteration (CNA). One software
package that is widely used for this purpose is CNVtools
(http://cnv-tools.sourceforge.net/) [8], which deals with large
CNA datasets. Other successful algorithms include Genomic
Identification of Significant Targets in Cancer (GISTIC) [9]
and its derivative JISTIC [10]. These algorithms identify
regions with aberrant copy number using statistical calcula-
tions and then confirm related genes by matching chromo-
some regions. We consider CNV analysis from a different
perspective: first, we reprocess the gene region, which we
call the pseudogene, and then generate a new type of data,
copy number alteration in array form (CNAR), at the gene
level. We present more details regarding our approach and its
applications in Methods and Results.
In the past decade, a number of useful andwell-organized
toolsets were developed for analyzing cancer phenotypes
or genotypes. However, most of these software packages
are commonly used to analyze gene-expression datasets.
For example, unsupervised clustering methods and super-
vised classification methods are applied to machine learning
algorithms in order to classify cancer phenotype, survival
time, cancer metastasis, and so forth. Such algorithms create
distinctions based on tissue RNA signatures for their predic-
tive and classification tasks. Certain tissue samples contain
macroscopic DNA variations which extend RNA variations
based on CNVs, especially in cancer.
Particularly in cancer tissue, distinctions, classifications,
and predictions based on such DNA variations may be
useful. Indeed, DNA variation in a tumor changes more
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 467514, 8 pages
http://dx.doi.org/10.1155/2015/467514
2 BioMed Research International
slowly than RNA variation and thus may be considered less
noisy. Therefore, it is worthwhile to consider DNA-based
algorithms.
If DNA copy number datasets (e.g., Agilent datasets)
could be reprocessed into formats that parallel RNA expres-
sion signatures obtained from microarrays, it would be
possible to construct DNA-based algorithms that parallel
existing algorithms based on RNA. To the extent that a
primary contributor to the expression level of a gene in
cancerous tissue is the corresponding gene copy number,
this type of analysis, using DNA copy number microarrays,
could be considered as a proxy for RNA microarrays. Given
that RNA signatures are more time-dependent than cancer-
cell DNA signatures, the latter provide a more stable set of
biomarkers for use in prediction of survival time, chemother-
apy response, and other outcomes.
2. Materials and Methods
Here we present an algorithm which reprocesses Agilent
DNA copy number signatures into a format that parallels the
microarray signatures used in standard software packages for
prediction and classification based on microarrays. Because
copy number datasets are provided with probe IDs, we first
need to download gene information to convert Agilent probe
positions to gene regions. The following describes the steps
for generation of CNARs corresponding to known genes.
Step 1 (obtain datasets). We downloaded 216 ovarian can-
cer (OV) and 215 glioblastoma multiforme (GBM) CNA
datasets, produced by Harvard Medical School using the
Agilent Human Genome Comparative Genomic Hybridiza-
tion Microarray 244A platform (HG-CGH-244A), updated
in 2012 from the TCGA data portal. The portal also provided
probe IDs with probe positions on the chromosome covered
by 60 base pairs (bp). We also selected two classes of
survival datasets for classification. From the GBM datasets,
we extracted 23 samples from patients whose survival time
was less than 100 days (short class) and 23 samples from
patients with survival time greater than 1500 days (long class).
From the OV datasets, we extracted 18 samples from patients
whose survival time was less than 1 year (short class) and 18
samples from patients whose survival time was greater than 5
years (long class). The survival times distinguishing the long
and short classes differed between GBM and OV because
GBM is a more fatal disease.
Step 2 (obtain gene and probe information). We downloaded
Agilent genome region from BioMart (http://www.biomart
.org/biomart/martview), which provides chromosome loca-
tion for each HGNC ID gene according to the HUGO gene
nomenclature committee (http://www.genenames.org/) [1].
Out of the 22,734 genes initially downloaded from BioMart,
the number of unique pseudogenes was 21,856. The HG-
CGH-244A platform contains 227,612 probe IDs.
Step 3 (extend the gene regions). We extended each gene
region by including 2000 bp for the promoter region and
100,000 bp on each side, the so-called pseudogene. Each
chromosome includes approximately 20 million base pairs,
and the number of genes in each chromosome is about
1000. Therefore, an expansion of 100,000 bp on each side
is reasonable. In addition, the region involved in CNV is
commonly much larger than the size of a gene. We note that
the range ofCNV is commonly 1 kb or larger [12].Thenumber
of probe IDs in the extended region is variable. The average
number of probes for each gene is 37 and each probe includes
60 bp. Therefore an average pseudogene covers additional
2220 bp, but not successively connected positions between
probes.
Step 4 (make the base matrix). First, we generated a sparse
matrix called the basematrix, with dimensions 21,856 (genes)
by 227,612 (probe IDs). Each component 𝐶
𝑖𝑗
of the base
matrix reports the existence of a probe ID, 𝑖th, corresponding
to a pseudogene 𝑗th by matching chromosome regions
obtained from Steps 2 and 3. The component could be 1 or 0
for existence of probe (a) or the average of number of probes
included in a corresponding gene presenting below (b). 𝑘 is







































is the 𝑖th probe and 𝑔
𝑗
represents the extended 𝑗th
gene region.
Step 5 (generate CNAR datasets). We combined all CNA
datasets from Step 1 into a single large matrix with probes in
rows and samples in columns. Next, we produced newCNAR
datasets as a simple product of matrices via multiplication of
one of the base matrices from Step 4 and a CNA data matrix.
Finally, we generated new CNAR datasets in matrix form,
presenting CNV in terms of gene names.
These comprehensive datasets allow a large class of gene-
expression software to be utilized to study DNA rather than
RNA signatures. In Figure 1, we illustrate how this software
works and demonstrate its application.
3. Results
To test our newly generated CNAR datasets, we implemented
well-knownmachine learning algorithms including unsuper-
vised cluster methods and supervised classification methods:
consensus clustering, silhouette clustering, and the support
vector machine (SVM).The Fisher criterion method [13] was













), representing the square of the difference in
means of two classes (𝐴, 𝐵) divided by the sum of the square
of their variances.
3.1. Application to Classification Methods (SVM) and Feature
Selection. We applied the newly generated CNAR datasets
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(b) Original datasets in (c) CNAR datasets in matrix form.
Values in cell are using
(a) Basic matrix of Step 4(a)
matrix form of Step 4(b)
Step 4(a)/Step 4(b)
Figure 1: Procedure for generation of CNAR datasets. (a) Basic matrix in Step 4, (b) original datasets of copy number alteration for each
probe. By multiplying (a) and (b), CNAR datasets were generated.
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Figure 2: (a) Plot for STOML3 in short and long classes of OV patients using CNAR datasets. (b) Plot for ZNF488 in short and long classes
of GBM patients. The 𝑦-axis represents CNAR level; the 𝑥-axis represents patients classes 1: short, 2: long.
to SVM with feature selection for classification of survival
in patients with OV (18 short and 18 long samples) and
GBM (23 short and 23 long samples). To avoid any prior
bias, the training of the classifier, the choice of the number
of features, and feature selection were done strictly in test
datasets. For evaluation, we used standard leave-one-out
cross validation (LOOCV). In OV, the best classification
accuracy of long versus short survival was 83.33%, using
four features. For GBM, the best classification accuracy of
long versus short survival was 82.61%, using 20 selected
features. The accuracies obtained using CNAR datasets were
higher than the accuracies obtained using gene-expression
microarray datasets (63.64% and 72.35% for OV and GBM,
resp.).
In OV datasets, since four-feature selection performed
best results, we collected all selected four features from all
train datasets as performing LOOCV. STOML3, including
eight CN probes from chr13:39482884 to chr13:39554832, was
selected in all training samples. The boxplots of STOML3
show the comparison of short survival patients to long sur-
vival patients (Figure 2(a)). In general, geneswith increases in
copy number represent oncogenes, and genes with decreases
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Table 1: Pathways enriched in OV and GBM: categories of molecular interaction and reactions, fromKEGG, are indicated: (1.1) carbohydrate
metabolism, (1.2) energy metabolism, (1.3) lipid metabolism, (1.8) metabolism of cofactors and vitamins, (1.9) metabolism of terpenoids and
polyketides, (1.11) xenobiotic biodegradation and metabolism, and (2.2) translation.
Pathways enriched in OV FDR Enriched in class
Pentose and glucuronate interconversion (1.1) 0 Long
Androgen and estrogen metabolism 0 Long
Porphyrin and chlorophyll metabolism (1.8) 0 Long
Aminoacyl tRNA biosynthesis (2.2) 0 Long
Carbon fixation in photosynthetic organisms (1.2) 0 Long
3-Chloroacrylic acid degradation 0 Short
Caprolactam degradation (1.11) 0 Short
Glycolysis and gluconeogenesis (1.1) 0 Short
Atrazine degradation (1.11) 0 Short
Polycyclic aromatic hydrocarbon degradation (1.11) 0 Short
Pathways enriched in GBM FDR Enriched in class
Linoleic acid metabolism (1.3) 0 Short
Arachidonic acid metabolism (1.3) 0 Short
Terpenoid backbone biosynthesis (1.9) 0 Short
Ether lipid metabolism (1.3) 0 Short
Pentose and glucuronate interconversion (1.1) 0 Long
Porphyrin and chlorophyll metabolism (1.8) 0 Long
in copy number represent tumor suppressors, which affect
short and long survival time, respectively. As shown in the
figure, mutation of this gene may cause cancer: if copy
number increases, then survival time is short, whereas if the
gene is lost, survival time is long. We also selected the most
significant gene, ZNF488, from the short and long class GBM
CNAR datasets. Our pseudogene region of ZNF488 is from
chr10:48355024 to chr10:48373866, including only one probe.
Figure 2(b) shows the comparison of short and long survival
patients. Since ZNF488 is related with antibody, the boxplot
shows consistency of the mechanism.
3.2. Application to Clustering Methods (Consensus and Sil-
houette Clustering). We applied the CNAR datasets to the
unsupervised consensus clustering algorithm [14] provided
in GenePattern [15] and Silhouettes [16]. We tested 215 GBM
samples with 204 genes out of 21,856 pseudogenes, setting
an arbitrary cutoff of the standard variance at 0.4. Figure 3
shows GBM clustering using CNAR datasets. Consensus
clustering in GenePattern using CNAR datasets of the 204
selected GBM genes is shown in Figure 3(a). We extracted
1740 genes inVerhaak et al. [11] which usedmRNAexpression
GBM datasets downloaded from TCGA. We also extracted
CNAR datasets of the 1740 genes and applied the datasets
to consensus clustering shown in Figure 3(b). In addition,
we demonstrated the performance of silhouette clustering
in Figure 3(c). We compared the clustering result of CNAR
datasets to the clustering result of mRNA expression datasets
in Verhaak et al. [11] using the same 1740 genes. The average
silhouette width is 0.18 in Verhaak et al., and our CNAR
datasets yielded a silhouette width of 0.52. Thus, CNAR
datasets yielded a superior clustering performance relative to
microarray expression data.
We also subjected OV CNAR datasets to the same
procedure. In that case, we downloaded 216 samples and
selected 175 genes with variance of 0.4, and the results are
shown in Figure 4 with a silhouette width of 0.21. Even
though clustering methods clearly separated the samples into
three groups, those groups were not related to survival time:
specifically, Kaplan-Meier survival curve analysis of these
three clustering groups did not reveal significant differences
(𝑃 = 0.09; data not shown).
In addition, we selected the gene with the largest gain in
copy number, EGFR, using standard deviation from theGBM
CNAR dataset. The distribution of CNAR in chromosome
7 is provided in Figure 5(a) for randomly selected 20 out of
215 samples. The 𝑦-axis represents CNAR level; the 𝑥-axis
represents genes in chromosome 7. Figure 5(a) reveals two
distinct classes plotting EGFR which includes 38 probes in
the regions chr7:54990071–chr7:55414419 in chromosome 7.
We applied the gene EGFR CNAR dataset to the consensus
clustering method provided in GenePattern [15] shown in
Figure 5(b).The plot is clearly distinct in two classes. Kaplan-
Meier plot of two distinct classes given by Figure 5(b) is
shown in Figure 5(c).
3.3. Application to Gene Set Enrichment Analysis. We sub-
jected CNAR datasets derived from OV and GBM samples
to gene set enrichment analysis (GSEA) [17]. The OV CNAR
survival datasets included 18 short class and 18 long class
samples, and the GBM datasets included 23 short class
and 23 long class samples. Table 1 shows the most enriched
pathways in OV and GBM, with a FDR cutoff of zero.
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(a)
k = 2 k = 3
(b)
Silhouette plot of pam (x = d1, k = 3)
3 clusters Cjn = 215
0.0 0.2 0.4 0.6 0.8 1.0
Average silhouette width: 0.52
1: 75 | 0.55
2: 71 | 0.44
3: 69 | 0.56
Silhouette width si
j: nj | avei∈Cj si
(c)
Figure 3: (a) Consensus clustering using CNAR datasets with 204 genes from 215 GBM samples from 𝑘 = 2 to 4. (b) Consensus clustering
using CNAR datasets with 1604 genes from 1740 genes selected from Verhaak et al. [11]. (c) Silhouette clustering plot using 1604 out of 1740
genes from CNAR.
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k = 2 k = 3 k = 4
(a)
Silhouette plot of pam (x = d1, k = 3)
3 clusters Cjn = 216
0.0 0.2 0.4 0.6 0.8 1.0
Average silhouette width: 0.21
1: 55 | 0.26
2: 72 | 0.22
3: 89 | 0.18
Silhouette width si
j: nj | avei∈Cj si
(b)
Figure 4: (a) Consensus clustering using CNAR datasets with 175 genes from 216 OV samples from 𝑘 = 2 to 𝑘 = 4. (b) Silhouette clustering
plot using the same (a) datasets.
The most enriched pathways in both cancers were related
to metabolism. In particular, the pentose and glucuronate
interconversion pathway and porphyrin and chlorophyll
metabolism were enriched in both OV and GBM.
4. Discussion
In this study, we generated new datasets that represented
DNA variation in formats that paralleled variation in RNA
expression and subjected the data to established machine
learning algorithms.Most previous studies identified changes
in DNA using CN alteration and then interpreted the rela-
tionship with genes by looking up the chromosome region.
These new CN alteration-based datasets, which we call CN
array (CNAR) datasets, could be used directly for identi-
fication of genetic variation at the RNA level. In addition,
the new CNAR datasets enable straightforward visualization
of gain or loss of pseudogenes along the chromosome. In
our analyses, we used several existing methods including
clustering, classification, and GSEA. In addition, we applied
CNAR datasets to two clustering methods, consensus clus-
tering and silhouette clustering.The clustering performances
were superior to those obtained using RNA expression. We
also applied CNAR to the SVM classification algorithm
for GBM and OV cancer patients stratified for short and
long survival times; the accuracies were 83.33% and 82.61%,
respectively. When we subjected CNAR datasets to GSEA,
we found two enriched metabolic pathways in both OV and
GBM with a FDR cutoff of zero. These new datasets enable
many applications, including clustering of cancer subtypes,
prediction of survival times, and classification of cancer
metastasis by analyzing DNA alterations using tools devel-
oped for RNA-level analysis. Such analysesmay provide novel
insights into the biological mechanisms underlying cancer.















































































































Figure 5: (a) Examples of CNAR across chromosome 7 for selected patients. The 𝑦-axis denotes the CNAR levels, and the 𝑥-axis denotes the
number of pseudogenes in chromosome 7. (b) Consensus clustering of EGFR CNAR datasets. (c) Kaplan-Meier survival analysis of EGFR
clusters given by (b) (log-rank 𝑃 value = 0.28).
The major limitation of this analysis is the fixed extension
of the gene region. Up to date there is no information for
extending gene region for copy number alteration.Therefore,
we need further study for extension method for each gene
region.
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